miércoles, 24 de junio de 2020

Fact Sheet for Healthcare Providers: Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit, Biohit Healthcare (Hefei) Co. Ltd. | NLM

Disaster Information Management Research Center | NLM

Disaster Information and Emergency Response

06/18/2020 12:00 AM EDT


Source: U.S. Food and Drug Administration (FDA). Published: 6/18/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit. The Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit is authorized for the detection of IgG and IgM antibodies to SARS-CoV-2 in serum, plasma (heparin, dipotassium EDTA, or sodium citrate) and venipuncture whole blood (heparin, dipotassium EDTA, or sodium citrate. (PDF)

No hay comentarios: